Please login to the form below

Not currently logged in

Servier abandons cancer drug collaboration with Pharmacyclics

Rights to lymphoma treatment abexinostat will be returned

Servier logoServier has ended its collaboration on a prospective new cancer treatment and will return abexinostat's global development and commercialisation rights to Pharmacyclics.

A pan-HDAC inhibitor, abexinostat is currently in phase II clinical trials for B-cell lymphoma and had been thought to have potential in other cancers.

Bob Duggan, chairman and CEO at Pharmacyclics, said: “Now that we have full ownership of the abexinostat asset, we will enter a period of further evaluation to determine its usefulness in oncology.”

A provisional patent application for abexinostat tosylate was filed with the US Patent and Trademark Office in 2013.

Pharmacyclics said it would now evaluate the opportunities that remain with the compound and would provide an update on the programme in mid 2015.

Article by
Kirstie Pickering

29th September 2014

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
GEM Marketing Ltd

GEM, a small but perfectly formed integrated marketing agency servicing the pharmaceutical industry....

Latest intelligence

The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...
When is it time to rebrand?